Peroxisome Proliferator-Activated Receptors and their Ligands in Cancer Drug- Resistance: Opportunity or Challenge
- PMID: 26845135
- DOI: 10.2174/1871520616666160204112941
Peroxisome Proliferator-Activated Receptors and their Ligands in Cancer Drug- Resistance: Opportunity or Challenge
Abstract
Development of resistance in cancer cells results in a high failure rate in cancer chemotherapy in the clinic. Therefore, investigating the mechanisms by which cancer cells acquire the capability to avoid cell death upon exposure to antineoplastic agents is of great significance in cancer research. In this review article, we will provide an overview of the mechanisms and molecular machinery of drug resistance in cancer cells which include but may not be limited to altered membrane transport and drug metabolizing enzymes, genetic response, enhanced DNA repair and alternation in the target molecules. A special focus will be on describing the strategies and the rationale for exploitation of peroxisome proliferator-activated receptors for overcoming the observed resistance in cancer cells.
Similar articles
-
Peroxisome Proliferator-Activated Receptor Ligands and Their Role in Chronic Myeloid Leukemia: Therapeutic Strategies.Chem Biol Drug Des. 2016 Jul;88(1):17-25. doi: 10.1111/cbdd.12737. Epub 2016 Mar 6. Chem Biol Drug Des. 2016. PMID: 26841308 Review.
-
The Anticancer Potential of Peroxisome Proliferator-Activated Receptor Antagonists.ChemMedChem. 2018 Feb 6;13(3):209-219. doi: 10.1002/cmdc.201700703. Epub 2018 Jan 10. ChemMedChem. 2018. PMID: 29276815 Review.
-
Differential effects of peroxisome proliferator-activated receptor agonists on doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.Cell Mol Biol (Noisy-le-grand). 2015 Dec 30;61(8):118-22. Cell Mol Biol (Noisy-le-grand). 2015. PMID: 26718439
-
Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer.J Cell Physiol. 2007 Jul;212(1):1-12. doi: 10.1002/jcp.20998. J Cell Physiol. 2007. PMID: 17443682 Review.
-
Targeting peroxisome proliferator-activated receptors: a novel strategy for Philadelphia chromosome-positive leukemia cells.Leuk Lymphoma. 2017 Nov;58(11):2762-2764. doi: 10.1080/10428194.2017.1312373. Epub 2017 May 15. Leuk Lymphoma. 2017. PMID: 28504032 No abstract available.
Cited by
-
Exercise and colorectal cancer: prevention and molecular mechanisms.Cancer Cell Int. 2022 Aug 9;22(1):247. doi: 10.1186/s12935-022-02670-3. Cancer Cell Int. 2022. PMID: 35945569 Free PMC article. Review.
-
Molecular iodine/doxorubicin neoadjuvant treatment impair invasive capacity and attenuate side effect in canine mammary cancer.BMC Vet Res. 2018 Mar 12;14(1):87. doi: 10.1186/s12917-018-1411-6. BMC Vet Res. 2018. PMID: 29530037 Free PMC article.
-
Cancer and diabetes: the interlinking metabolic pathways and repurposing actions of antidiabetic drugs.Cancer Cell Int. 2021 Sep 17;21(1):499. doi: 10.1186/s12935-021-02202-5. Cancer Cell Int. 2021. PMID: 34535145 Free PMC article. Review.
-
Involvement of IGF/IGFBP/Erk axis in the exercise-mediated preventive effects on colorectal cancer in rats.Int J Clin Exp Pathol. 2021 May 15;14(5):608-617. eCollection 2021. Int J Clin Exp Pathol. 2021. PMID: 34093946 Free PMC article.
-
Epithelial Ovarian Cancer: A Five Year Review.Medicina (Kaunas). 2023 Jun 21;59(7):1183. doi: 10.3390/medicina59071183. Medicina (Kaunas). 2023. PMID: 37511995 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources